350 related articles for article (PubMed ID: 27091709)
1. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
[TBL] [Abstract][Full Text] [Related]
2. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
3. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
Leung HW; Chan AL
Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
7. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.
Abdel-Qadir H; Tai F; Croxford R; Austin PC; Amir E; Calvillo-Argüelles O; Ross H; Lee DS; Thavendiranathan P
Circ Heart Fail; 2021 Jul; 14(7):e008110. PubMed ID: 34187164
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
10. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
11. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
12. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
13. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
[TBL] [Abstract][Full Text] [Related]
17. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
18. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
19. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]